In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.
In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, medical oncologist, Northwell Health, led a conversation with Luis E. Raez, MD, the medical director and chief scientific officer at Memorial Cancer Institute, Memorial Health Care System and a member of the Florida Society of Clinical Oncology (FLASCO), about EGFR exon 20–mutated lung cancer.
The first component of deciding how to treat patients with genomic testing is to identify the mutation(s) present. Seetharamu and Raez both weigh in on the question of how soon and how often oncologists should test patients with lung cancer for mutations.
Once the EGFR exon 20 mutation is identified in a patient with lung cancer, one targeted therapy that is FDA-approved for the treatment of the patient subgroup is osimertinib (Tagrisso). Another agent, cetuximab (Erbitux) is being explored in the space after demonstrating promise in EGFR-mutated colorectal cancer as well as head and neck cancers. Finally, the novel EGFR inhibitor poziotinib is currently under investigation in the clinical trial setting, in addition to mobocertinib (formerly TAK-788) and TAS6417.
An ongoing need in the lung cancer field is determining how to sequence these available and potential therapies for the treatment of patients with EGFR exon 20–mutated disease.
First-Line Amivantamab Plus Lazertinib Represents New SOC in Advanced EGFR+ NSCLC
October 23rd 2023Amivantamab-vmjw with lazertinib showed positive survival results vs osimertinib as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.
Read More
Tepotinib Continues to Show Positive Outcomes in METex14-Skipping NSCLC
October 23rd 2023In the VISION trial, tepotinib led to clinically meaningful results in treatment-naïve and pretreated patients with METex14-skipping non–small cell lung cancer, supporting the use of MET inhibitors for this patient population.
Read More